{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T03:00:11Z","timestamp":1791687611303,"version":"4.3.4"},"reference-count":31,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T00:00:00Z","timestamp":1717977600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jaci-inpractice.org","clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.jaip.2024.05.052","type":"journal-article","created":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T01:45:10Z","timestamp":1717983910000},"page":"2399-2407.e5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["Real-World Data on Tezepelumab in Patients With Severe Asthma in Germany"],"prefix":"10.1016","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8132-7958","authenticated-orcid":false,"given":"Leonie","family":"Biener","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"M\u00fcmmler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher Alexander","family":"Hinze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrik","family":"Suhling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Korn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Fisser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arne","family":"Biener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Pizarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Lenoir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Hackl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Skowasch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Milger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2024.05.052_bib1","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/1471-2458-12-204","article-title":"Global asthma prevalence in adults: findings from the cross-sectional world health survey","volume":"12","author":"To","year":"2012","journal-title":"BMC Public Health"},{"key":"10.1016\/j.jaip.2024.05.052_bib2","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1183\/09031936.00202013","article-title":"International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma","volume":"43","author":"Chung","year":"2014","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2024.05.052_bib3","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1080\/03007995.2018.1505352","article-title":"Systematic literature review of the clinical, humanistic, and economic burden associated with asthma uncontrolled by GINA steps 4 or 5 treatment","volume":"34","author":"Chen","year":"2018","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jaip.2024.05.052_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2023.108551","article-title":"Biologics for severe asthma and beyond","volume":"252","author":"M\u00fcmmler","year":"2023","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jaip.2024.05.052_bib5","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00528-2020","article-title":"Treatment options in type-2 low asthma","volume":"57","author":"Hinks","year":"2021","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2024.05.052_bib6","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1080\/14728222.2020.1783242","article-title":"Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma","volume":"24","author":"Gauvreau","year":"2020","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.jaip.2024.05.052_bib7","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","article-title":"Tezepelumab in adults and adolescents with severe, uncontrolled asthma","volume":"384","author":"Menzies-Gow","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2024.05.052_bib8","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S2213-2600(22)00492-1","article-title":"Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study","volume":"11","author":"Menzies-Gow","year":"2023","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2024.05.052_bib10","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jaci.2009.06.053","article-title":"The minimally important difference of the Asthma Control Test","volume":"124","author":"Schatz","year":"2009","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2024.05.052_bib11","series-title":"S2k-gudelines for the specialists\u2019 diagnosis and treatment of asthma (S2k-Leitlinie zur fach\u00e4rztlichen Diagnostik und Thrapie von Asthma)","author":"Lommatzsch","year":"2023"},{"key":"10.1016\/j.jaip.2024.05.052_bib12","article-title":"Criteria for evaluation of response to biologics in severe asthma\u2014the Biologics Asthma Response Score (BARS)","author":"Milger","year":"2023","journal-title":"Pneumologie"},{"key":"10.1016\/j.jaip.2024.05.052_bib13","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1056\/NEJMoa1704064","article-title":"Tezepelumab in adults with uncontrolled asthma","volume":"377","author":"Corren","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2024.05.052_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2022.106793","article-title":"The German severe asthma patient: baseline characteristics of patients in the German Severe Asthma Registry, and relationship with exacerbations and control","volume":"195","author":"Korn","year":"2022","journal-title":"Respir Med"},{"key":"10.1016\/j.jaip.2024.05.052_bib15","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.3390\/biom13071118","article-title":"Type 2 low biomarker stability and exacerbations in severe uncontrolled asthma","volume":"13","author":"Viinanen","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.jaip.2024.05.052_bib16","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.3390\/biomedicines11041226","article-title":"T2-low asthma: a discussed but still orphan disease","volume":"11","author":"Peri","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.jaip.2024.05.052_bib17","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.3390\/biomedicines9111684","article-title":"Characterization of T2-low and T2-high asthma phenotypes in real-life","volume":"9","author":"Ricciardolo","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.jaip.2024.05.052_bib18","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1136\/thoraxjnl-2018-212233","article-title":"Impact of an increase in the inhaled corticosteroid dose on blood eosinophils in asthma","volume":"74","author":"Lommatzsch","year":"2019","journal-title":"Thorax"},{"key":"10.1016\/j.jaip.2024.05.052_bib19","first-page":"357","article-title":"Impact of short-term pausing of oral corticosteroids on blood eosinophil count in patients with severe asthma","volume":"77","author":"Biener","year":"2022","journal-title":"Pneumologie"},{"key":"10.1016\/j.jaip.2024.05.052_bib20","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2147\/JAA.S328653","article-title":"Real world biologic use and switch patterns in severe asthma: data from the International Severe Asthma Registry and the US CHRONICLE Study","volume":"15","author":"Menzies-Gow","year":"2022","journal-title":"J\u00a0Asthma Allergy"},{"key":"10.1016\/j.jaip.2024.05.052_bib21","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.anai.2023.08.006","article-title":"Retrospective assessment and Biologic Asthma Response Score reveal roadmap for switching biologics in severe asthma","volume":"132","author":"Kayser","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2024.05.052_bib22","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3389\/fmed.2020.00191","article-title":"Airway remodeling in asthma","volume":"7","author":"Hough","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jaip.2024.05.052_bib23","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S2213-2600(21)00537-3","article-title":"Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled, phase 3 study","volume":"10","author":"Wechsler","year":"2022","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2024.05.052_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.opresp.2022.100231","article-title":"Efficacy and potential positioning of tezepelumab in the treatment of severe asthma","volume":"5","author":"Plaza","year":"2023","journal-title":"Open Respir Arch"},{"key":"10.1016\/j.jaip.2024.05.052_bib25","doi-asserted-by":"crossref","first-page":"A14","DOI":"10.1016\/j.chest.2022.08.014","article-title":"Wayfinder: a phase 3b, single-arm study to evaluate the efficacy and safety of tezepelumab in reducing oral corticosteroids (OCS) use in OCS-dependent patients with severe asthma","volume":"162","author":"Menzies-Gow","year":"2022","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2024.05.052_bib26","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1016\/j.jaip.2023.05.047","article-title":"Response to biologics and clinical remission in the Adult German Asthma Net Severe Asthma Registry Cohort","volume":"11","author":"Milger","year":"2023","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2024.05.052_bib27","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1159\/000534924","article-title":"Adverse effects under Th2 biologics (dupilumab and tezepelumab) in a patient with severe asthma and atopic dermatitis","volume":"102","author":"Suhling","year":"2023","journal-title":"Respiration"},{"key":"10.1016\/j.jaip.2024.05.052_bib28","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jdcr.2021.12.011","article-title":"Review of dupilumab-associated inflammatory arthritis: an approach to clinical analysis and management","volume":"21","author":"Jay","year":"2022","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jaip.2024.05.052_bib29","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1186\/s12890-021-01785-z","article-title":"Real-world study in severe eosinophilic asthma patients refractory to anti-IL5 biological agents treated with benralizumab in Spain (ORBE study)","volume":"21","author":"Mart\u00ednez-Morag\u00f3n","year":"2021","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.jaip.2024.05.052_bib30","doi-asserted-by":"crossref","first-page":"609","DOI":"10.2147\/JAA.S311975","article-title":"Effectiveness of switching biologics for severe asthma patients in Japan: a single-center retrospective study","volume":"14","author":"Numata","year":"2021","journal-title":"J\u00a0Asthma Allergy"},{"key":"10.1016\/j.jaip.2024.05.052_bib31","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.jaip.2020.09.014","article-title":"Dupilumab improves asthma control and lung function in patients with insufficient outcome during previous antibody therapy","volume":"9","author":"M\u00fcmmler","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"EFirst","key":"10.1016\/j.jaip.2024.05.052_bib32","article-title":"Criteria for evaluation of response to biologics in severe asthma \u2013 the Biologics Asthma Response Score (BARS)","author":"Milger","year":"2023","journal-title":"Pneumologie [Internet]"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219824006251?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219824006251?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T07:50:36Z","timestamp":1732175436000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219824006251"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S2213219824006251"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2024.05.052","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-World Data on Tezepelumab in Patients With Severe Asthma in Germany","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2024.05.052","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}